Amylyx Pharmaceuticals, Inc. (AMLX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$27.20-4.80%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Amylyx Pharmaceuticals, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.371
Annual ending 2026-12-31
Revenue	—	80,625
EPS	—	-1.496
Annual ending 2027-12-31
Revenue	—	56.55M
EPS	—	-1.132

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Develop AMX0318 for rare diseases	It is developing a new drug candidate AMX0318 for rare diseases.	Intact	AMX0318 development stalls or is discontinued	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain cash runway into 2028	The company aims to maintain cash runway into 2028.	Improving	Cash runway falls short of 2028 based on operating plans	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2. Cash and equivalents declined from $279.8M at 2026-Q1 to $250.8M at 2026-Q2, consistent with operating cash outflows. Management continues to expect cash runway into 2028, aligning with current operating plans. The trajectory is delivering given the maintained runway despite ongoing losses. Delivery assessment Oct 24, 2026
Reduce losses toward break-even	A primary condition in Amylyx Pharmaceuticals, Inc.'s published investment case. The stated target is EPS improves from -$0.46 in 2025 toward break-even.	Improving	EPS remains below -$0.46 or worsens through FY27	Diluted EPS: $-0.39 per share FY2026-Q2; GAAP. Published target: EPS improves from -$0.46 in 2025 toward break-even. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-0.39 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 215e8310-d2c6-4b82-94eb-7b539b71c464. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.13

$-1.26 → $-1.13 · observed estimates

FY2027 revenue$0.06B

$0.04B → $0.06B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.26	$38,996,660	8 / 10
2026-07-25	$-1.26	$38,996,660	8 / 10
2026-07-26	$-1.36	$29,364,070	7 / 9
2026-07-27	$-1.36	$29,364,070	7 / 9
2026-07-28	$-1.34	$33,030,904	6 / 6
2026-07-29	$-1.36	$29,364,070	7 / 9
2026-07-30	$-1.36	$29,364,070	7 / 9
2026-07-31	$-1.36	$29,364,070	7 / 9
2026-08-01	$-1.36	$29,364,070	7 / 9
2026-08-02	$-1.36	$29,364,070	7 / 9
2026-08-03	$-1.36	$29,364,070	7 / 9
2026-08-04	$-1.36	$29,364,070	7 / 9
2026-08-05	$-1.36	$29,364,070	7 / 9
2026-08-06	$-1.36	$29,423,470	7 / 9
2026-08-07	$-1.34	$33,097,732	6 / 6
2026-08-08	$-1.34	$33,101,410	7 / 8
2026-08-09	$-1.34	$34,404,020	7 / 8
2026-08-10	$-1.34	$34,404,020	7 / 8
2026-08-11	$-1.38	$29,313,000	7 / 6
2026-08-12	$-1.38	$29,313,000	7 / 6
2026-08-13	$-1.38	$32,043,250	7 / 9
2026-08-14	$-1.35	$32,043,252	6 / 6
2026-08-15	$-1.35	$32,043,252	6 / 6
2026-08-16	$-1.35	$32,043,252	6 / 6
2026-08-17	$-1.35	$32,043,252	6 / 6
2026-08-18	$-1.35	$32,043,252	6 / 6
2026-08-19	$-1.35	$32,043,252	6 / 6
2026-08-20	$-1.35	$32,043,252	6 / 6
2026-08-21	$-1.20	$56,197,107	7 / 7
2026-08-22	$-1.20	$56,197,107	7 / 7
2026-08-23	$-1.20	$56,197,107	7 / 7
2026-08-24	$-1.20	$56,197,107	7 / 7
2026-08-25	$-1.20	$56,197,107	7 / 7
2026-08-26	$-1.20	$56,197,107	7 / 7
2026-08-27	$-1.20	$56,197,107	7 / 7
2026-08-28	$-1.20	$56,197,107	7 / 7
2026-08-29	$-1.18	$56,487,107	7 / 7
2026-08-30	$-1.18	$56,487,107	7 / 7
2026-08-31	$-1.18	$56,487,107	7 / 7
2026-09-01	$-1.18	$56,487,107	7 / 7
2026-09-02	$-1.18	$56,487,107	7 / 7
2026-09-03	$-1.18	$56,487,107	7 / 7
2026-09-04	$-1.18	$56,487,107	7 / 7
2026-09-05	$-1.18	$56,487,107	7 / 7
2026-09-06	$-1.18	$56,487,107	7 / 7
2026-09-07	$-1.18	$56,487,107	7 / 7
2026-09-08	$-1.18	$56,487,107	7 / 7
2026-09-09	$-1.18	$56,487,107	7 / 7
2026-09-10	$-1.18	$56,487,107	7 / 7
2026-09-11	$-1.18	$56,487,107	7 / 7
2026-09-12	$-1.18	$56,487,107	7 / 7
2026-09-13	$-1.18	$56,487,107	7 / 7
2026-09-14	$-1.18	$56,487,107	7 / 7
2026-09-15	$-1.18	$56,487,107	7 / 7
2026-09-16	$-1.18	$56,487,107	7 / 7
2026-09-17	$-1.18	$56,487,107	7 / 7
2026-09-18	$-1.18	$56,487,107	7 / 7
2026-09-19	$-1.18	$56,487,107	7 / 7
2026-09-20	$-1.18	$56,487,107	7 / 7
2026-09-21	$-1.18	$56,487,107	7 / 7
2026-09-22	$-1.18	$56,487,107	7 / 7
2026-09-23	$-1.18	$56,487,107	7 / 7
2026-09-24	$-1.18	$56,487,107	7 / 7
2026-09-25	$-1.18	$56,487,107	7 / 7
2026-09-26	$-1.18	$56,487,107	7 / 7
2026-09-27	$-1.18	$56,487,107	7 / 7
2026-09-28	$-1.18	$56,487,107	7 / 7
2026-09-29	$-1.18	$56,487,107	7 / 7
2026-09-30	$-1.18	$56,487,107	7 / 7
2026-10-01	$-1.18	$56,487,107	7 / 7
2026-10-02	$-1.18	$56,487,107	7 / 7
2026-10-03	$-1.18	$56,487,107	7 / 7
2026-10-04	$-1.18	$56,487,107	7 / 7
2026-10-05	$-1.18	$56,487,107	7 / 7
2026-10-06	$-1.18	$56,487,107	7 / 7
2026-10-07	$-1.18	$56,487,107	7 / 7
2026-10-08	$-1.18	$56,487,107	7 / 7
2026-10-09	$-1.18	$56,487,107	7 / 7
2026-10-10	$-1.18	$56,487,107	7 / 7
2026-10-11	$-1.18	$56,487,107	7 / 7
2026-10-12	$-1.18	$56,487,107	7 / 7
2026-10-13	$-1.18	$56,487,107	7 / 7
2026-10-14	$-1.18	$56,487,107	7 / 7
2026-10-15	$-1.18	$56,487,107	7 / 7
2026-10-16	$-1.13	$56,549,480	7 / 7
2026-10-17	$-1.13	$56,549,480	7 / 7
2026-10-18	$-1.13	$56,549,480	7 / 7
2026-10-19	$-1.13	$56,549,480	7 / 7
2026-10-20	$-1.13	$56,549,480	7 / 7
2026-10-21	$-1.13	$56,549,480	7 / 7
2026-10-22	$-1.13	$56,549,480	7 / 7
2026-10-23	$-1.13	$56,549,480	7 / 7
2026-10-24	$-1.13	$56,549,480	7 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	11	1
2026-06-01	11	1
2026-07-01	11	1
2026-08-01	11	1
2026-09-01	11	1
2026-10-01	11	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Develop AMX0318 for rare diseasesQualitative condition
Maintain cash runway into 2028Qualitative condition
Reduce losses toward break-evenDiluted EPS: $-0.39 per share

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.2%Typical daily move · historical

Downside history

-33.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Amylyx Pharmaceuticals, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotech story, not a proven earnings compounder. The long-term thesis is in a watch state: the LUCIDITY trial delivered positive topline results, but approval and commercial execution are still ahead.

What's priced into Amylyx Pharmaceuticals, Inc.

The evidence snapshot does not provide a valuation level or a clear account of what the market already assumes, so valuation and expectations are hard to assess. It reports low fragility, but that does not establish that the shares are cheap, fair, or expensive.

What the fundamentals likely do

Near term, losses and weak recent financial performance remain, and the company has a run of earnings misses; the snapshot flags the next earnings report as worth watching. For the multi-year thesis, management plans to submit an NDA by the end of 2026 and potentially launch avexitide in 2027 if approved; cash declined between the first and second quarters of 2026, while management continues to expect runway into 2028.

What Amylyx Pharmaceuticals, Inc. hinges on

The central swing factor is whether the positive LUCIDITY results, including a 55% reduction in hypoglycemic events, lead to a successful regulatory review and launch. Guidance cuts, continued weakening in the jobs report, or litigation could add pressure; stronger results and guidance from healthcare sector leaders could support sector momentum.